Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “outperform” rating reissued by investment analysts at BMO Capital Markets in a research note issued to investors on Friday, September 22nd, Marketbeat reports. They presently have a $134.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $99.00. BMO Capital Markets’ price objective indicates a potential upside of 14.05% from the stock’s previous close.
ALNY has been the subject of several other reports. Chardan Capital set a $110.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, June 12th. ValuEngine upgraded Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Ladenburg Thalmann Financial Services set a $90.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Monday, July 17th. BidaskClub upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Finally, JMP Securities boosted their price objective on Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 20th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $94.33.
Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down 0.66% on Friday, hitting $117.49. 813,963 shares of the company traded hands. The stock’s market capitalization is $10.78 billion. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $119.02. The firm’s 50 day moving average price is $81.14 and its 200-day moving average price is $69.12.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). The business had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business’s quarterly revenue was up 82.9% on a year-over-year basis. During the same period last year, the company posted ($1.05) earnings per share. On average, equities research analysts expect that Alnylam Pharmaceuticals will post ($5.19) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Earns Outperform Rating from BMO Capital Markets” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://ledgergazette.com/2017/10/01/alnylam-pharmaceuticals-inc-alny-stock-rating-reaffirmed-by-bmo-capital-markets.html.
In other news, President Barry E. Greene sold 76,815 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at $16,539,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of ALNY. Bank of Montreal Can boosted its holdings in Alnylam Pharmaceuticals by 283.6% in the first quarter. Bank of Montreal Can now owns 9,528 shares of the biopharmaceutical company’s stock worth $488,000 after purchasing an additional 7,044 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $256,000. Nationwide Fund Advisors boosted its holdings in Alnylam Pharmaceuticals by 30.5% in the first quarter. Nationwide Fund Advisors now owns 11,583 shares of the biopharmaceutical company’s stock worth $594,000 after purchasing an additional 2,707 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Alnylam Pharmaceuticals by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 305,682 shares of the biopharmaceutical company’s stock worth $15,666,000 after purchasing an additional 2,899 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $148,000. 94.25% of the stock is currently owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.